Lemaitre Vascular (LMAT) Research & Development (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of Research & Development data on file, last reported at $14.5 million in Q1 2026.

• On a quarterly basis, Research & Development rose 2.13% year-over-year to $14.5 million in Q1 2026; TTM through Mar 2026 was $35.9 million, a 15.62% decrease from a year earlier, with the FY2025 full-year figure at $14.1 million, down 69.75% from the prior year.
• Research & Development for Q1 2026 stood at $14.5 million, up from $3.5 million in the prior quarter.
• Over the last five years, Research & Development for LMAT reached as high as $14.9 million in Q2 2025 and fell as low as -$13.8 million in Q4 2023.
• Historically, Research & Development has averaged $5.6 million across 5 years, with a median of $4.3 million in 2024.
• Across the five-year window, Research & Development tumbled 157.1% in 2022 and jumped 247.69% in 2025, its largest moves.
• Year by year, Research & Development stood at -$11.0 million in 2022, then decreased by 25.33% to -$13.8 million in 2023, then jumped by 191.36% to $12.6 million in 2024, then slumped by 72.02% to $3.5 million in 2025, then surged by 310.84% to $14.5 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $14.5 million in Q1 2026, $3.5 million in Q4 2025, and $3.0 million in Q3 2025.